EDSA - Edesa Biotech, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.3000
-0.0700 (-2.08%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close3.3700
Open3.4000
Bid0.0000 x 1000
Ask0.0000 x 900
Day's Range3.2000 - 3.4000
52 Week Range1.5800 - 13.5600
Volume43,337
Avg. Volume63,454
Market Cap29.235M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.7260
Earnings DateAug 13, 2020 - Aug 15, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • EDSA: Interim Analysis of Phase 2b Trial of EB01 in second half of 2020…
    Zacks Small Cap Research

    EDSA: Interim Analysis of Phase 2b Trial of EB01 in second half of 2020…

    By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Update on Phase 2b Trial of EB01 Edesa Biotech, Inc. (NASDAQ:EDSA) is currently conducting a Phase 2b clinical trial of EB01 2.0% cream in patients with ACD. The randomized, double blind, placebo controlled, sample size adaptive design trial is expected to enroll approximately 46 patients in Part A randomized 1:1

  • Companies Like Edesa Biotech (NASDAQ:EDSA) Can Be Considered Quite Risky
    Simply Wall St.

    Companies Like Edesa Biotech (NASDAQ:EDSA) Can Be Considered Quite Risky

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

  • ACCESSWIRE

    Edesa Biotech Reports Fiscal 2nd Quarter 2020 Results

    TORONTO, ON / ACCESSWIRE / May 15, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three and six months ended March 31, 2020 ...

  • Zacks Small Cap Research

    EDSA: Licenses Two Potential COVID-19 Treatments…

    By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Licenses Two Assets for Potentially Treating COVID-19 On April 20, 2020, Edesa Biotech, Inc. (NASDAQ:EDSA) announced an exclusive licensing agreement with Light Chain Bioscience for two clinical-stage monoclonal antibody assets targeting toll-like receptor 4 (TLR4) and C-X-C motif chemokine 10 (CXCL10). Light Chain

  • ACCESSWIRE

    Edesa Biotech and Light Chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other Disorders

    TORONTO, ON / ACCESSWIRE / April 20, 2020 / Edesa Biotech, Inc. (EDSA), a clinical-stage biopharmaceutical company, today announced a strategic agreement with Light Chain Bioscience (a brand of NovImmune SA), a leading Swiss pharmaceutical development company, for an exclusive worldwide license to develop and commercialize two Phase 2-ready biologic drug candidates for all therapeutic, prophylactic and diagnostic applications. Edesa plans to pursue the development of these signaling molecules as potential treatments for acute respiratory distress syndrome and lung injury resulting from viral respiratory infections, such as the coronavirus that causes COVID-19, and other disorders.

  • ACCESSWIRE

    Edesa Biotech to Develop Novel Treatment for Vitiligo in Collaboration with the National Research Council of Canada

    TORONTO, ON / ACCESSWIRE / March 12, 2020 / Edesa Biotech, Inc. (EDSA), a clinical-stage biopharmaceutical company, today announced a collaborative research project with the National Research Council of Canada (NRC) to develop novel immunotherapies for vitiligo as well as other indications. Vitiligo is a life-altering autoimmune disease that results in the depigmenting of the skin. People who have vitiligo develop white patches of skin due to the destruction of special cells called melanocytes which produce the skin pigment melanin.

  • ACCESSWIRE

    Edesa Biotech Reports Fiscal 1st Quarter 2020 Results

    TORONTO, ON / ACCESSWIRE / February 13, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three months ended December 31, 2019 ...

  • ACCESSWIRE

    Edesa Biotech Announces $4.36 million Registered Direct Offering

    TORONTO, ON / ACCESSWIRE / January 6, 2020 / Edesa Biotech, Inc. (EDSA), a clinical-stage biopharmaceutical company, today announced that it has entered into definitive securities purchase agreements with certain institutional and accredited investors as well as company insiders in a registered direct offering of an aggregate of 1,355,380 common shares. In a concurrent private placement, the company agreed to sell to such investors Class A Purchase Warrants to purchase an aggregate of up to 1,016,553 of the company's common shares, or 0.75 of a common share for each share purchased in the offering, and Class B Purchase Warrants to purchase an aggregate of up to 677,703 of the company's common shares, or 0.50 of a common share for each share purchased in the offering.

  • ACCESSWIRE

    Edesa Biotech Reports Financial Results for Short Period Fiscal Year

    TORONTO, ON / ACCESSWIRE / December 12, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the nine-month period ended September ...

  • ACCESSWIRE

    Edesa Biotech Reports Positive Healthy Volunteer Data and Expands Phase 2b Dermatitis Study to Patients with Facial Lesions

    TORONTO, ON / ACCESSWIRE / December 3, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported that the company's lead product candidate, EB01, has demonstrated positive safety data in healthy volunteers participating in its ongoing Phase 2b clinical study in chronic allergic contact dermatitis (ACD), a debilitating disease that is frequently caused by allergens present in the workplace. The healthy volunteer cohort at the outset of Edesa's study is designed to clear the way for using the experimental topical treatment on the face of ACD patients. Due to the high prevalence of symptoms on the face of ACD patients, the expansion of the study to facial symptoms is expected to address a key aspect of the disease, while broadening the potential patient population.

  • ACCESSWIRE

    Edesa Biotech Announces Upcoming Conference Schedule

    TORONTO, ON / ACCESSWIRE / November 5, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that its management will present at the H.C. Wainwright 5th Annual Israel Conference in Tel Aviv, Israel. Edesa completed a reverse acquisition with a Nasdaq listed company in June of this year and has since initiated a Phase 2b clinical study of its lead product candidate in allergic contact dermatitis.

  • ACCESSWIRE

    Edesa Biotech Enrolls First Patient in Phase 2b Dermatitis Study

    TORONTO, ON / ACCESSWIRE / October 21, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced that the first patient has been enrolled in a Phase 2b clinical trial evaluating the company's lead product candidate, EB01, as a monotherapy for patients with moderate to severe chronic allergic contact dermatitis (ACD). The U.S. Food and Drug Administration recently approved Edesa's clinical protocol and provided a "safe to proceed" letter, which formally authorized the company to begin its clinical investigation. In the first cohort, ACD patients will be treated for 28 days with EB01 cream, an investigational medicine that contains a non-steroidal anti-inflammatory compound known as an sPLA2 inhibitor.

  • ACCESSWIRE

    Edesa Biotech to Present at H. C. Wainwright Global Investment Conference

    TORONTO, ON / ACCESSWIRE / August 29, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, will present at the H. C. Wainwright 21st Annual Global Investment Conference to be held September 8-10, 2019 in New York City. Edesa senior management will be available during the conference for one-on-one meetings. Members of the investment community who are interested in meeting with the company should contact conference coordinators to arrange an appointment or contact Edesa directly via email at investors@edesabiotech.com.

  • ACCESSWIRE

    Edesa Biotech Reports Quarterly Financial Results

    TORONTO, ON / ACCESSWIRE / August 14, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three and six months ended June 30, ...

  • ACCESSWIRE

    Edesa Biotech Completes Manufacturing for Upcoming Dermatitis Study

    TORONTO, ON / ACCESSWIRE / July 25, 2019 / Edesa Biotech, Inc. (NASDAQ: EDSA), a clinical-stage biopharmaceutical company, reported today that the company has completed the manufacturing of its lead drug candidate EB01, a novel sPLA2 inhibitor that Edesa is developing as a potential treatment for chronic allergic contact dermatitis (ACD). Edesa is currently evaluating investigational centers in the U.S. and expects to proceed with enrolling the first patient into its Phase 2b clinical trial in the current quarter. “We have completed the manufacturing of our active pharmaceutical ingredient and have the drug product for the first cohort ready to distribute to our investigational centers in the U.S.,” said Michael Brooks , President of Edesa.

  • Edesa Biotech (EDSA) Stock Rockets Higher on Dermatitis Study Approval
    InvestorPlace

    Edesa Biotech (EDSA) Stock Rockets Higher on Dermatitis Study Approval

    Edesa Biotech (NASDAQ:EDSA) stock is flying higher on Thursday after getting approval from the U.S. Food and Drug Administration (FDA).Source: Shutterstock The approval from the FDA is for Edesa Biotech to move forward with a study of EB01. This is a novel sPLA2 inhibitor that the company is working on. It hopes to use it to treat chronic allergic contact dermatitis.According to Edesa Biotech, this approval will allow it to start a Phase 2b clinical protocol and clinical investigation into the drug. The company says that it is planning to enroll the first patient in the study starting sometime next quarter.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"There are limited options for ACD patients and we have been pleased with the level of interest from physicians in the U.S.," Dr. Par Nijhawan, CEO of Edesa Biotech, said in a statement. "The company is committed to rapidly advancing our clinical plans and remains on track to initiate our clinical study for EB01." * 6 Stocks Ready to Bounce on a Trade Deal Edesa Biotech says that it will be performing a randomized, double-blind, vehicle-controlled, sample size adaptive design study of the drug's ability to treat chronic allergic contact dermatitis. This will have patients using various EB01 creams with different strengths over a 28-day period. It also points out that the study may include up to 166 patients.EDSA stock was up 115% as of noon Thursday, but is down 26% since the start of the year. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Blue-Chip Stocks to Buy for a Noisy Market * 5 Strong Buy Biotech Stocks for the Second Half * 6 Stocks Ready to Bounce on a Trade Deal As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Edesa Biotech (EDSA) Stock Rockets Higher on Dermatitis Study Approval appeared first on InvestorPlace.

  • PR Newswire

    Edesa Biotech Receives Approval to Proceed with U.S. Clinical Study

    TORONTO, June 20, 2019 /PRNewswire/ -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company, reported today that the U.S. Food and Drug Administration has notified the company that it may proceed with its clinical investigation of EB01, a novel sPLA2 inhibitor, which Edesa is developing as a potential treatment for chronic allergic contact dermatitis. The FDA "safe to proceed" letter formally approves the company's Phase 2b clinical protocol and authorizes the company to begin its clinical investigation.